Methotrexate (MTX) and 6-mercaptopurine, important components of acute lymphoblastic leukemia (ALL) treatment, are substrates for multidrug resistance associated protein MRP4. Eight single nucleotide polymorphisms (SNP) were analyzed in MRP4 gene and four variants were identified as tagSNPs with frequency ≥ 5%. They were investigated for association with treatment responses in 275 children with ALL. The TC genotype of the regulatory T-1393C polymorphism was associated with better event free survival (EFS, p=0.02) and lower MTX plasma levels (p=0.01). The CA genotype of A934C (Lys304Asn) substitution correlated in contrast with lower EFS (p=0.02) and higher frequency of high-grade thrombocytopenia (p=0.01). Gene reporter assay showed that the promoter haplotype uniquely tagged by C-1393 allele conferred higher promoter activity in comparison to remaining haplotypes (p<0.0001). Further analyses are needed to replicate this pilot study and get closer insight into the functional effect of these polymorphisms.
Introduction
The treatment of pediatric acute lymphoblastic leukemia (ALL) has greatly improved due to the introduction of effective combination risk-adapted therapies.
1,2 Nevertheless, therapy resistance in a significant number of children is still a major obstacle to successful treatment whereas intensive treatment has also important side effects. Pharmacogenetic studies identified certain genetic variations that may contribute to variability in ALL treatment responses. 1, 2 The drug effects depend, among other factors, on the activity and expression of multidrug resistancerelated proteins (MRPs). 3 MRP4 has a remarkable ability to transport a range of drugs and physiological substrates. 4 MRP4 is ubiquitously expressed including high expression in the hematopoietic cells thus possibly affecting both drug intended and drug side effects in these cells. 5 MRP4 affects disposition of physiological folates, but also of methotrexate (MTX) and 6-mercaptopurine (6-MP), which are key components of ALL treatment. 4, [6] [7] [8] MRP4 protects cells against thiopurine-induced toxicity by actively exporting thioguanine nucleotides (TGN) 6 , whereas MRP4 transfected cells displayed increased resistance to MTX 4, 7 . Wide variation in MRP4 expression has been reported in pediatric leukemia lymphoblasts. 9 This can be in part due to functional genetic polymorphisms. Here we report the analysis of MRP4 gene variations.
Patients and methods
The children enrolled in the study are 275 Caucasians diagnosed for ALL at Hospital Figure S1 ). Selected tagSNPs (single nucleotide polymorphism sufficient to define common haplotypes) with frequency ≥ 5% (T-1393C, C-1015T, C934A and A4131C)
were subsequently genotyped in 275 ALL patients. Genotyping details are given in Table S1 . (Table   S2 ). Toxicity on bone marrow and liver function (the appearance of toxicity and toxicity rates) was based, as previously described 20 , on the results of weekly laboratory tests collected in 174 patients during consolidation and maintenance treatment. MTX plasma levels at both 36h and 48h following high dose (HD)-MTX were available for 197 patients; 267 patients had measured or conclusive MTX levels at 72h post HD-MTX. All analyses were performed by SPSS statistical package (Chicago, IL) version 13.0.
For the gene reporter experiments, haplotype-specific fragments corresponding to proximal promoter of MRP4 were amplified from genomic DNA of individuals with known genotype, and subcloned into the promoterless pGL3-basic firefly luciferase reporter vector (Promega) as previously described. 10 Expression data for lymphoblastoid cells lines were taken from gene expression omnibus at NCBI.
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Results and discussion
Association of MRP4 genotypes with event free survival (EFS) showed that individuals with the TC-1393 genotype had better EFS and those with the CA934 genotype had reduced EFS in comparison to remaining genotypes (p=0.02, Figure 1A ). When two polymorphisms were combined, three genotype groups could be distinguished with EFS decreasing from 95% to 80% and 62% ( Figure 1A ). Significant associations with EFS were retained in the Cox regression, when other prognostic factors or genotypes previously shown to affect EFS 10, [12] [13] [14] [15] [16] [17] [18] [19] were included into the models (Table S2 ). Among event-predisposing genotypes, MRP4 CA934, DFHR haplotype *1 and TS 3R homozygosity retained significance (p ≤ 0.05). DHFR and TS, in accordance with our previous observation 10 , result in more important EFS reduction when acting together; MRP4 leads to equally important reduction individually and combined with other genotypes ( Figure S1 ).
Increase in the frequency of thrombocytopenia grade 3/4 was seen for individuals with MRP4 CA934 genotype (p=0.01, Figure 2A ), whereas differences in MTX plasma levels were observed for MRP4 -1393 variation, being lowest in patients with TC genotype (p=0.01 for MTX retention at 72 hours post HD-MTX, Figure 2B and p=0.006 for 36h and 48h post HD-MTX levels, Figure 2C ).
In this study the A allele of C934A (Lys304Asn) correlated with reduced EFS and higher incidence of high-grade thrombocytopenia. The functional impact of this polymorphism has not been clearly shown. There was no difference in protein expression in liver or in accumulation of 6-MP and antiviral agents in kidney cells in relation to the MRP4 genotypes. 8, 22 Gradhand et al 23 , in contrast, showed reduction in MRP4 expression in liver samples associated with A934 allele. Owing to the small number of patients the significance of this finding was not conclusive. We also noticed non-significant reduction in mRNA expression in lympoblastoid cell lines (p=0.2, Figure 1B ). One of possible explanation for our finding is that higher frequency of toxicity presumably associated with lower MRP4 expression would lead to more frequent drug withdrawal or dose reduction which might cause higher frequency of relapse. Indeed, relapsed ALL patients do not have higher MRP4 expression, contrasting other MRPs whose higher levels correlated with a relapse 24 . MRP4 was also expressed at a lower level in T-cell ALL having higher resistance to treatment than B-cell ALL. 24 The other mechanisms are likely involved as well; down-regulation of MRPs might result in decreased folate efflux thereby leading to expansion of the intracellular folate pool and antifolate resistace. and has affinity for many substrates. 4 MTX levels assessed in this study likely reflect renal MRP4 transport and not the efflux from lymphocytes given that the renal excretion is the main MTX elimination route. 4 Higher MRP4 activity in kidney associated with C-1393 allele could then explain lower MTX levels and absence of toxicity associated with this allele. MRP4 was also shown to protect cells against 6-MP hematopoietic toxicity 6 . It would be thus important to
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From correlate these polymorphisms with 6-MP/TGN levels, which was not possible in this study due to the lack of 6-MP/TGN data.
Several additional non-synonymous polymorphisms were identified in MRP gene. Few of them were found to influence protein expression or drug transport. 6, 8, 22 Given their low frequency (1-2%) they were not here analyzed.
In conclusion, we provided additional insight into the possible genetic modulation of treatment responses in childhood ALL. Further functional analysis and replication in independent cohort are needed to support the validity of this pilot study.
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